These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38333550)

  • 1. Pb-214/Bi-214-TCMC-Trastuzumab inhibited growth of ovarian cancer in preclinical mouse models.
    Metebi A; Kauffman N; Xu L; Singh SK; Nayback C; Fan J; Johnson N; Diemer J; Grimm T; Zamiara M; Zinn KR
    Front Chem; 2023; 11():1322773. PubMed ID: 38333550
    [No Abstract]   [Full Text] [Related]  

  • 2. (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Mol Cancer Ther; 2012 Mar; 11(3):639-48. PubMed ID: 22238365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Br J Cancer; 2013 May; 108(10):2013-20. PubMed ID: 23632482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD46 targeted
    Li J; Huang T; Hua J; Wang Q; Su Y; Chen P; Bidlingmaier S; Li A; Xie Z; Bidkar AP; Shen S; Shi W; Seo Y; Flavell RR; Gioeli D; Dreicer R; Li H; Liu B; He J
    J Exp Clin Cancer Res; 2023 Mar; 42(1):61. PubMed ID: 36906664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation of
    Westrøm S; Generalov R; Bønsdorff TB; Larsen RH
    Nucl Med Biol; 2017 Aug; 51():1-9. PubMed ID: 28486098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methodology for labeling proteins and peptides with lead-212 (212Pb).
    Baidoo KE; Milenic DE; Brechbiel MW
    Nucl Med Biol; 2013 Jul; 40(5):592-9. PubMed ID: 23602604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of
    Yong K; Brechbiel M
    AIMS Med Sci; 2015; 2(3):228-245. PubMed ID: 26858987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
    Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
    Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1119-26. PubMed ID: 23200172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model.
    Yong KJ; Milenic DE; Baidoo KE; Kim YS; Brechbiel MW
    Cancer Med; 2013 Oct; 2(5):646-53. PubMed ID: 24403230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.
    Meredith R; Torgue J; Shen S; Fisher DR; Banaga E; Bunch P; Morgan D; Fan J; Straughn JM
    J Nucl Med; 2014 Oct; 55(10):1636-42. PubMed ID: 25157044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.
    Meredith RF; Torgue JJ; Rozgaja TA; Banaga EP; Bunch PW; Alvarez RD; Straughn JM; Dobelbower MC; Lowy AM
    Am J Clin Oncol; 2018 Jul; 41(7):716-721. PubMed ID: 27906723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease.
    Milenic DE; Garmestani K; Brady ED; Albert PS; Abdulla A; Flynn J; Brechbiel MW
    Clin Cancer Res; 2007 Mar; 13(6):1926-35. PubMed ID: 17363549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H3-targeted
    Kasten BB; Arend RC; Katre AA; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
    Nucl Med Biol; 2017 Apr; 47():23-30. PubMed ID: 28104527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Efficacy of
    Dekempeneer Y; Caveliers V; Ooms M; Maertens D; Gysemans M; Lahoutte T; Xavier C; Lecocq Q; Maes K; Covens P; Miller BW; Bruchertseifer F; Morgenstern A; Cardinaels T; D'Huyvetter M
    Mol Pharm; 2020 Sep; 17(9):3553-3566. PubMed ID: 32787284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial.
    Milenic DE; Baidoo KE; Brechbiel MW
    Pharmaceuticals (Basel); 2015 Jul; 8(3):435-54. PubMed ID: 26230702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging, biodistribution, and toxicology evaluation of (212)Pb-TCMC-trastuzumab in nonhuman primates.
    Kasten BB; Azure MT; Schoeb TR; Fisher DR; Zinn KR
    Nucl Med Biol; 2016 Jul; 43(7):391-6. PubMed ID: 27179247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
    Faratian D; Zweemer AJ; Nagumo Y; Sims AH; Muir M; Dodds M; Mullen P; Um I; Kay C; Hasmann M; Harrison DJ; Langdon SP
    Clin Cancer Res; 2011 Jul; 17(13):4451-61. PubMed ID: 21571868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted alpha therapy with the
    Tornes AJK; Stenberg VY; Larsen RH; Bruland ØS; Revheim ME; Juzeniene A
    Front Med (Lausanne); 2022; 9():1058863. PubMed ID: 36507500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.
    Meredith RF; Torgue J; Azure MT; Shen S; Saddekni S; Banaga E; Carlise R; Bunch P; Yoder D; Alvarez R
    Cancer Biother Radiopharm; 2014 Feb; 29(1):12-7. PubMed ID: 24229395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.